GTx, Inc. (NASDAQ:GTXI) CEO Marc Steven Hanover sold 7,309 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $11.33, for a total transaction of $82,810.97. Following the completion of the sale, the chief executive officer now directly owns 129,990 shares in the company, valued at approximately $1,472,786.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of GTx, Inc. (NASDAQ:GTXI) opened at $11.15 on Thursday. The firm has a market cap of $240.19, a PE ratio of -6.37 and a beta of 1.77. GTx, Inc. has a 52 week low of $2.73 and a 52 week high of $13.35.
GTX (NASDAQ:GTXI) last released its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.25). equities analysts anticipate that GTx, Inc. will post -1.61 earnings per share for the current fiscal year.
A number of research firms recently weighed in on GTXI. Robert W. Baird began coverage on shares of GTX in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $17.00 target price on the stock. Zacks Investment Research cut shares of GTX from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Stifel Nicolaus began coverage on shares of GTX in a research note on Thursday, November 9th. They issued a “buy” rating on the stock.
A number of large investors have recently added to or reduced their stakes in the business. Abingworth LLP acquired a new position in GTX in the third quarter valued at about $2,781,000. Caxton Corp acquired a new position in GTX in the third quarter valued at about $531,000. Finally, Bank of New York Mellon Corp acquired a new position in GTX in the second quarter valued at about $124,000. Hedge funds and other institutional investors own 11.57% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Marc Steven Hanover Sells 7,309 Shares of GTx, Inc. (GTXI) Stock” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/11/marc-steven-hanover-sells-7309-shares-of-gtx-inc-gtxi-stock.html.
GTX Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.